2024
A Randomized Trial of Hypofractionated Post-Mastectomy Radiation Therapy (PMRT) in Women with Breast Reconstruction (RT CHARM, Alliance A221505)
Poppe M, Le-Rademacher J, Haffty B, Hansen E, Agarwal J, Wagner J, Kong I, Armer J, Arthur D, Whelan T, Lee M, Kour O, Lustberg M, Partridge A, Carey L, Ruddy K, Gaffney D, Stecklein S, Bernstein M, Khan A. A Randomized Trial of Hypofractionated Post-Mastectomy Radiation Therapy (PMRT) in Women with Breast Reconstruction (RT CHARM, Alliance A221505). International Journal Of Radiation Oncology • Biology • Physics 2024, 120: s11. DOI: 10.1016/j.ijrobp.2024.07.002.Peer-Reviewed Original ResearchPost-mastectomy radiation therapyNeoadjuvant chemotherapyBreast reconstructionComplication rateReconstruction complicationsBreast cancerNon-inferiorityHigh-risk breast cancerBody mass index >Conventionally fractionated radiationGenetic predisposition genesImplant-only reconstructionsMedian Follow-UpImmediate breast reconstructionOne-sided type I errorNon-inferiority marginStandard of careHypofractionated radiationRegional recurrenceRadiation therapyTumor characteristicsInvasive BCAdjuvant chemotherapyPredisposition genesMedian ageRadiation therapy for triple-negative breast cancer: from molecular insights to clinical perspectives
Kim J, Fahmy V, Haffty B. Radiation therapy for triple-negative breast cancer: from molecular insights to clinical perspectives. Expert Review Of Anticancer Therapy 2024, 24: 211-217. PMID: 38502143, DOI: 10.1080/14737140.2024.2333320.Peer-Reviewed Original ResearchTriple-negative breast cancerPoly (ADP-ribose) polymeraseLocoregional controlRadiation therapyBreast cancerImpact of post-mastectomy radiation therapyPost-mastectomy radiation therapyEffects of radiotherapySynergistic effects of radiotherapyPersonalized treatment approachesImproved survival ratesIntegration of radiomicsImmunotherapy combinationsBRCA1/2 mutationsRadiotherapy responseOvercome radioresistanceTargeted radiosensitizationImprove patient outcomesRadiosensitizing strategiesNovel radiosensitizersTarget biological pathwaysTreatment strategiesTreatment outcomesMolecular profilingRadiotherapy
2017
Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer?
Chagpar AB, Horowitz N, Sanft T, Wilson LD, Silber A, Killelea B, Moran MS, DiGiovanna MP, Hofstatter E, Chung G, Pusztai L, Lannin DR. Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer? The American Journal Of Surgery 2017, 214: 1082-1088. PMID: 28939252, DOI: 10.1016/j.amjsurg.2017.07.036.Peer-Reviewed Original ResearchConceptsHormone receptor-positive breast cancerReceptor-positive breast cancerPositive breast cancerLymph nodesRadiation therapyBreast cancerPost-lumpectomy radiation therapyPost-mastectomy radiation therapyNational Cancer DatabaseSentinel LN biopsyBreast cancer patientsWomen 70 yearsAdjuvant chemotherapyAdjuvant therapyHormonal therapyLN biopsyLN evaluationLN statusCancer patientsCancer DatabasePatientsTherapyCancerChemotherapyHr
2009
QS109. Validation of a Clinical Prediction Rule for Patients' Likelihood of Requiring Post-Mastectomy Radiation Therapy
Chagpar A, Blumencranz P, Whitworth P, Deck K, Rosenberg A, Simmons R, Reintgen D, Beitsch P, Julian T, Saha S, Giuliano A, McMasters K, Mamounas E. QS109. Validation of a Clinical Prediction Rule for Patients' Likelihood of Requiring Post-Mastectomy Radiation Therapy. Journal Of Surgical Research 2009, 151: 287. DOI: 10.1016/j.jss.2008.11.405.Peer-Reviewed Original ResearchPost-mastectomy radiation therapyClinical prediction rulePatient's likelihoodRadiation therapyPrediction ruleTherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply